Aaron Tachibana Sells 4,982 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 4,982 shares of Personalis stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $14.00, for a total transaction of $69,748.00. Following the sale, the chief financial officer owned 198,833 shares of the company’s stock, valued at $2,783,662. The trade was a 2.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Tachibana also recently made the following trade(s):

• On Friday, June 26th, Aaron Tachibana sold 51,251 shares of Personalis stock. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18.
• On Thursday, June 4th, Aaron Tachibana sold 40,000 shares of Personalis stock. The stock was sold at an average price of $12.01, for a total transaction of $480,400.00.
• On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The shares were sold at an average price of $11.58, for a total transaction of $449,292.42.

Personalis Stock Performance

Shares of NASDAQ PSNL opened at $13.40 on Wednesday. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -13.14 and a beta of 2.28. The stock has a 50 day moving average price of $8.69 and a 200 day moving average price of $8.34. Personalis, Inc. has a 52-week low of $3.84 and a 52-week high of $14.07.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The firm had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. Analysts forecast that Personalis, Inc. will post -1.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PSNL. BTIG Research decreased their price objective on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Wall Street Zen downgraded shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Finally, Morgan Stanley reduced their price target on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Personalis has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. lifted its stake in shares of Personalis by 273.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after purchasing an additional 7,896,714 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Personalis by 1,332.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock valued at $11,531,000 after purchasing an additional 1,347,439 shares during the last quarter. Kennedy Capital Management LLC raised its holdings in Personalis by 196.2% in the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after purchasing an additional 1,281,695 shares in the last quarter. Aberdeen Group plc raised its holdings in Personalis by 36.1% in the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after purchasing an additional 861,948 shares in the last quarter. Finally, ARK Investment Management LLC raised its holdings in Personalis by 11.3% in the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after purchasing an additional 802,268 shares in the last quarter. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.